Prevention With the Health and Lifestyle Tool

Sponsor
Region Skane (Other)
Overall Status
Recruiting
CT.gov ID
NCT05006508
Collaborator
(none)
77,000
1
2
40.5
1900.8

Study Details

Study Description

Brief Summary

In this study participants will be randomized to use a digital lifestyle tool over three years or to a control group without access to the tool. The investigators will prospectively via clinical registries follow the incidence and development of type 2 diabetes over three years in those using the tool regularly and those in the control group.

Condition or Disease Intervention/Treatment Phase
  • Behavioral: Lifestyle tool
N/A

Detailed Description

Considerable evidence suggest that lifestyle changes can prevent or delay the onset of type 2 diabetes, and self-care behaviors largely determine HbA1c. Modifiable lifestyle factors have been established as key drivers of disease onset, progression, and prognosis, motivating the use of "lifestyle as medicine".

Digital health tools are increasingly incorporated into diabetes care, and have the potential to improve both behavioral and clinical outcomes on a broad basis. However, low levels of uptake, reduced user engagement over time, and low acceptance among patients, raise concerns about their effectiveness.

The objective or this study is to evaluate a new web-based tool, developed at the University Gothenburg, Sweden, that aims to support patient autonomy and motivation to make sustainable lifestyle changes.

The investigators will test the hypothesis that individuals who have access to the tool get lower incidence of type 2 diabetes or in case they already have diabetes develop improved glucose control compared with control individuals. The participants will complete the Findrisc questionnaire to assess the risk for type 2 diabetes to enable analysis of high-risk individuals.

The study is an investigator-initiated single-center study conducted over three years.

The tool is web-based and used via a computer or mobile phone. It is used at each individual's preferred pace but participants are recommended to login at least every other week. Every round the participants choose a themes (out of appr. 80 possible covering e.g. food, exercise, stress, self-reflection aspects), which takes appr. 15-30 minutes to complete. Participants then reflect on the content and how it could be implemented in daily life. When returning for next round participants are asked to reflect on any changes done since last time. There is no interaction between individual participants.

There will be two primary endpoints:
  1. Incidence of type 2 diabetes as measured in non-diabetic participants with increased risk for type 2 diabetes (controls vs. those using the tool regularly)

  2. Change of HbA1c, reflecting long-term blood glucose control, from baseline to end of follow-up in participants who have type 2 diabetes (controls vs. those using the tool regularly).

Study Design

Study Type:
Interventional
Anticipated Enrollment :
77000 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Intervention Model Description:
Participants get access to the tool or get assigned to a control group without access.Participants get access to the tool or get assigned to a control group without access.
Masking:
None (Open Label)
Primary Purpose:
Prevention
Official Title:
Prevention and Development of Lifestyle Diseases With the Health and Lifestyle Tool
Actual Study Start Date :
Aug 16, 2021
Anticipated Primary Completion Date :
Aug 15, 2024
Anticipated Study Completion Date :
Dec 31, 2024

Arms and Interventions

Arm Intervention/Treatment
Experimental: Usage of tool

Participants get access to the tool and use it regularly

Behavioral: Lifestyle tool
Regular use of the digital Lifestyle tool

No Intervention: Controls on usual care

Participants who get randomized to control cannot access the tool and get no further follow-up. Their development of type 2 diabetes or development of HbA1c is tracked via clinical registries.

Outcome Measures

Primary Outcome Measures

  1. Incidence of type 2 diabetes [3 years]

    Incidence of type 2 diabetes defined as random plasma glucose >11.1 mmol/L or fasting glucose >7.0 mmol/L or HbA1C ≥6.5% compared between participants regularly using the tool and on usual care.

  2. Change of long-term blood glucose concentration measured as glycated hemoglobin at end of follow-up [3 years]

    Intraindividual change of long-term blood glucose concentration measured as glycated hemoglobin (HbA1c) at end of follow-up relative to baseline compared between participants regularly using the tool and on usual care.

Eligibility Criteria

Criteria

Ages Eligible for Study:
35 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
Yes
Inclusion Criteria:
  • informed consent

  • Age above 35 years

Exclusion Criteria:
  • type 1 diabetes, MODY or secondary diabetes

  • conditions or treatments that in the judgement of the Investigator could affect the study evaluation

  • connection with the study team, funders, authorities, universities or other public or private bodies in such a way that specific interests in the study outcomes could be suspected.

Contacts and Locations

Locations

Site City State Country Postal Code
1 Anders Rosengrentest Malmö Skane Sweden 20502

Sponsors and Collaborators

  • Region Skane

Investigators

  • Principal Investigator: Anders Rosengren, Prof, Göteborg University

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Region Skane
ClinicalTrials.gov Identifier:
NCT05006508
Other Study ID Numbers:
  • Lifestyle1
First Posted:
Aug 16, 2021
Last Update Posted:
Apr 6, 2022
Last Verified:
Mar 1, 2022
Individual Participant Data (IPD) Sharing Statement:
Yes
Plan to Share IPD:
Yes
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No

Study Results

No Results Posted as of Apr 6, 2022